Publication | Closed Access

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

MedicineCancer ManagementMito End-3GynecologyRecurrent Endometrial CancerCancer TreatmentPhase 2OncologyRadiation OncologyGynecology Oncology